Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks

Executive Summary

The broad labeling that FDA approved for Benlysta, the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.

You may also be interested in...

Amid A Flurry Of EU Positive Opinions Benlysta And Yervoy Shine, While Fampyra Is Reborn

The European Medicines Agency has recommended an impressive number of drugs for approval, including Merck & Co's hepatitis C therapy, Victrelis, Theravance's Vibativ and Amgen's Xgeva.

HGS Wastes No Time Investing In Pipeline Beyond Benlysta

One week after receiving FDA approval for its breakthrough lupus drug, Human Genome Sciences is spending $50 million for broad rights to an early-stage cancer drug that hits a popular target.

Deals Of The Week: Eisai/Epizyme, AstraZeneca/Galderma, Evotec/Harvard

Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts